phi-101
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 8, 2020 (NCT04842370)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
FLT3 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
NC(=O)Nc1cc(C#Cc2cccc(F)c2)sc1C(=O)N[C@H]1CCCNC1- Mol. weight
- 386.45 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4802136 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04678102 | Phase 1 | Dec 15, 2020 | Pharos Life Corporation, Seoul National University |
| NCT04842370 | Phase 1 | Jun 8, 2020 | Pharos Life Corporation, Seoul National University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pharos Life Corporation | For profit | 2 | 0 | 1 | 2020 |
| Seoul National University | Academic/Hospital | 2 | 2 | 1 | 2020 |
2 organizations
Page 1 / 1